Microscopy innovator Chromodynamics raises €2 million
Deep tech company Chromodynamics announces that it has raised €2 million in seed funding.
Published on November 25, 2024
Chromodynamics announced their new investment during the Gerard & Anton Founders Dinner. © Bram van Dal
The funding comes from the investment fund KIKK Capital. This funding will enable Chromodynamics to complete the development of its innovative microscopy product and launch it commercially into the biomedical research market. Based at the High Tech Campus in Eindhoven, the company is on a path towards a global launch of its fully automated microscope platform, designed to identify cells in tissue samples autonomously.
Predicting how a patient will respond
During drug development, hundreds of compounds must be screened for efficacy and safety. Additionally, predicting how an individual patient will respond to a drug remains challenging due to incomplete insights into the body’s immune response. The interactions between numerous tissue components must be mapped to accurately characterize an immune response. Conventional microscopy images and statistical datasets without spatial information (e.g., from flow cytometry) fail to deliver this essential information. Existing methods for identifying cells in tissue samples are complex, costly, and take months to complete. Chromodynamics’ solution reduces this process to under a week.
Entering the next phase
“It is really exciting to secure the funding needed to realize our vision.”, says Wouter Vijvers, founder and CEO of Chromodynamics. “Over the past years, we have done so much market validation and technology development to prove that we have a winner in our hands. Now, we can enter the next phase. Our solution improves upon the state-of-the-art by an order of magnitude on all important performance metrics (throughput, ease-of-use, level of detail), while dramatically reducing costs for the customer.”
Immunotherapies for cancer
Chromodynamics is prioritizing the completion of product development for a launch in the beachhead translational research market, with a focus on accelerating drug development, particularly immunotherapies for cancer. In the long-term, the platform is expected to evolve into a diagnostic tool for personalized medicine.
Innovative microscope promises gold standard for diagnosis of gout, pseudogout and osteoarthritis
Crystalytics recently received funding from LIOF to market an innovative device.